Validation of POMS questionnaire in postmenopausal women

Wyrwich, Kathleen W.; Yu, Holly

doi:10.1007/s11136-011-9846-2

Cited by 38 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the POMS 2-Y, alpha coefficients ranged from .76 to .95 for the normative sample, and from .78 to .96 for the clinical sample (Heuchert & McNair, 2012, p. 37). These findings are similar to those for the original POMS (e.g., Curran et al, 1995;Gibson, 1997;O'Halloran, Murphy, & Webster 2004;Wyrwich & Yu, 2011).…”

Section: Internal Consistencysupporting

confidence: 85%

“…The POMS and its short-forms have been used with various populations of medical patients (Curran, Andrykowski & Studts 1995;Guadagnoli & Mor, 1989;Wyrwich & Yu, 2011;Baker, Denniston, Zabora, Polland, & Dudley 2002;Walker, Sprague, Sleator, & Ullmann 1988), children (Walker et al, 1988), adolescents (Terry, Lane, & Fogarty 2003), university students (Barker-Collo, 2003;Reddon, Marceau, & Holden 1985), working adults (Morfeld, Petersen, Kruger-Bodeker, von Mackensen, & Bullinger 2007), athletes (Bell & Howe, 1988) and older adults (Gibson, 1997;Shin & Colling, 2000;Nyenhuis, Yamamoto, Luchetta, Terrien, & Parmentier 1999). Construction of the POMS 2-A was based on a normative sample of 1000 North American adults, with stratified random sampling to approximate the USA 2000 census.…”

Section: Samplementioning

confidence: 99%

See 1 more Smart Citation

Measures of Affect Dimensions

Boyle

Helmes

Matthews

et al. 2015

Measures of Personality and Social Psychological Constructs

View full text Add to dashboard Cite

Section: Internal Consistencysupporting

confidence: 85%

Section: Samplementioning

confidence: 99%

Measures of Affect Dimensions

Boyle

Helmes

Matthews

et al. 2015

Measures of Personality and Social Psychological Constructs

View full text Add to dashboard Cite

“…Pain and Nausea were measured on an 11 point verbal scale, with 0 representing no pain or no nausea, and a score of 10 representing the most pain or nausea ever experienced. Anxiety was measured by the Profile of Mood States Anxiety Tension Short Form (POMS-SF) (Wyrwich and Yu, 2011). …”

Section: Methodsmentioning

confidence: 99%

Exploring the multifactorial nature of postoperative nausea and vomiting in women following surgery for breast cancer

Wesmiller

Sereika

Bender

et al. 2017

Autonomic Neuroscience

View full text Add to dashboard Cite

Background Postoperative nausea and vomiting (PONV) are two of the most frequent and distressing complications following surgical procedures, with as many as 80% of patients considered to be at risk. Despite recognition of well-established risk factors and the subsequent use of clinical guidelines, 20–30% of women do not respond to antiemetic protocols, indicating that there may be a genetic risk. Objective The purpose of this pilot study was to describe the incidence and explore the risk factors associated with PONV after surgery in women diagnosed with early stage breast cancer. Methods A prospective cohort design was employed to measure PONV in women recruited prior to surgery. DNA was extracted from saliva samples collected prior to discharge. Polymorphisms for seven candidate genes with a known role in one of the neural pathways associated with PONV were included in this study; serotonin receptor (HTR3A), serotonin transport (SLC6A4), tryptophan (TPH), dopamine receptors (DRD2/ANKK and DRD3), catechol-O-methyltransferase (COMT) and histamine (H1). Results Twenty-nine (29.8%) women experienced nausea and 10 (11%) experienced nausea and vomiting while in the PACU despite administration of multiple antiemetic medications. Women who experienced PONV had higher levels of pain and received more opioids than those women who did not experienced PONV. Odds ratios demonstrated that alleles for the COMT, DRD3, and TPH genes were associated with decreased PONV. Conclusion The understanding of the multifactorial nature of PONV and the recognition of genetic risk will ultimately lead to the development of personalized interventions to manage these frequent and often debilitating symptoms.

show abstract

“…Secondary endpoint measures included the Hot Flash Related Daily Interference Scale (HFRDIS) [27], the Profile of Mood States (POMS) [28, 29], and a Side Effect Questionnaire (SEQ). The SEQ was completed weekly at the end of each week for weeks 1–7, while the HFRDIS and POMS were completed twice, at the end of week 1 and at week 7.…”

Section: Statistical Considerationsmentioning

confidence: 99%

Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes

Kadakia

Loprinzi

Atherton

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

Purpose Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. Methods This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25 %. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2–7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. Results From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6 %, respectively. When compared to the historical placebo response of 25 %, the effect of SAMe on hot flash score was not statistically significant (p=0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. Conclusions The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.

show abstract

Validation of POMS questionnaire in postmenopausal women

Abstract: These data demonstrate the internal consistency and validity of the POMS to measure mood among postmenopausal women with moderate to severe hot flushes and the responsiveness of the POMS among these women with greater mood symptoms.

Cited by 38 publications

References 23 publications

Measures of Affect Dimensions

Measures of Affect Dimensions

Exploring the multifactorial nature of postoperative nausea and vomiting in women following surgery for breast cancer

Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes

Contact Info

Product

Resources

About